Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

Published:2018-06-12 Issue:1 Volume:37 Page:143-153
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Zhang Jianzhong,Li Xiao,Yang Bin,Wu Cheng,Fan Yanghua,Li Hongjun^ORCID

Funder

National Natural Science Foundation of China

Natural Science Foundation of Beijing Municipality

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/article/10.1007/s00345-018-2370-z/fulltext.html

Reference41 articles.

1. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099–1109. https://doi.org/10.1016/j.eururo.2014.12.038

2. Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA (2011) Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 29:179–184. https://doi.org/10.1007/s00345-010-0605-8

3. Alawamlh OAH, Goueli R, Lee RK (2018) Lower urinary tract symptoms, benign prostatic hyperplasia, and urinary retention. Med Clin N Am 102:301–311. https://doi.org/10.1016/j.mcna.2017.10.005

4. Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 15:463. https://doi.org/10.1007/s11934-014-0463-9

5. Yuan JQ, Mao C, Wong SY, Yang ZY, Fu XH, Dai XY, Tang JL (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore). 94:e974. https://doi.org/10.1097/md.0000000000000974

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis;Scientific Reports;2024-05-15

2. A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia;Arab Journal of Urology;2023-06-13

3. Treatment of benign prostatic hyperplasia: Update and future;Urological Science;2023

4. Ultrasound-guided perineal laser ablation versus prostatic arterial embolization for benign prostatic hyperplasia: two similar short-term efficacies;Acta Radiologica;2022-11-27

5. Therapeutic effect of acupuncture and moxa combustion on prostate hyperplasia;Medicine;2022-10-07